These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29920652)

  • 1. Pharmacogenetics of Clopidogrel Therapy and Neurointerventional Procedures: We Need Precision Data for Precision Medicine.
    Rakicevic L; Nestorovic A
    Clin Pharmacol Ther; 2019 Mar; 105(3):547-549. PubMed ID: 29920652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.
    Shuldiner AR; Palmer K; Pakyz RE; Alestock TD; Maloney KA; O'Neill C; Bhatty S; Schub J; Overby CL; Horenstein RB; Pollin TI; Kelemen MD; Beitelshees AL; Robinson SW; Blitzer MG; McArdle PF; Brown L; Jeng LJ; Zhao RY; Ambulos N; Vesely MR
    Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):76-84. PubMed ID: 24616408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage optimization of clopidogrel via a precision medicine approach: the way forward.
    V Aswathy SP; Chandra KR; Jyothikrishna P; Arun KP
    Pharmacogenomics; 2022 Feb; 23(3):195-206. PubMed ID: 35112572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?
    Knauer MJ; Diamandis EP; Hulot JS; Kim RB; So DY
    Clin Chem; 2015 Oct; 61(10):1235-40. PubMed ID: 26272232
    [No Abstract]   [Full Text] [Related]  

  • 5. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
    Empey PE; Stevenson JM; Tuteja S; Weitzel KW; Angiolillo DJ; Beitelshees AL; Coons JC; Duarte JD; Franchi F; Jeng LJB; Johnson JA; Kreutz RP; Limdi NA; Maloney KA; Owusu Obeng A; Peterson JF; Petry N; Pratt VM; Rollini F; Scott SA; Skaar TC; Vesely MR; Stouffer GA; Wilke RA; Cavallari LH; Lee CR;
    Clin Pharmacol Ther; 2018 Oct; 104(4):664-674. PubMed ID: 29280137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV
    Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel pharmacogenetics: Beyond candidate genes and genome-wide association studies.
    Lewis JP; Shuldiner AR
    Clin Pharmacol Ther; 2017 Mar; 101(3):323-325. PubMed ID: 27649515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.
    Pulley JM; Denny JC; Peterson JF; Bernard GR; Vnencak-Jones CL; Ramirez AH; Delaney JT; Bowton E; Brothers K; Johnson K; Crawford DC; Schildcrout J; Masys DR; Dilks HH; Wilke RA; Clayton EW; Shultz E; Laposata M; McPherson J; Jirjis JN; Roden DM
    Clin Pharmacol Ther; 2012 Jul; 92(1):87-95. PubMed ID: 22588608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
    Mohammad AM; Al-Allawi NAS
    J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institutional profile: University of Florida Health Personalized Medicine Program.
    Cavallari LH; Weitzel KW; Elsey AR; Liu X; Mosley SA; Smith DM; Staley BJ; Winterstein AG; Mathews CA; Franchi F; Rollini F; Angiolillo DJ; Starostik P; Clare-Salzler MJ; Nelson DR; Johnson JA
    Pharmacogenomics; 2017 Apr; 18(5):421-426. PubMed ID: 28346068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need of a multicomponent guiding approach to personalize clopidogrel treatment.
    Valeria C; Carmine S; Valentina M; Teresa I; Maria C; Martina T; Giancarlo A; Giovanna N; Graziamaria C; Amelia F
    Pharmacogenomics J; 2021 Apr; 21(2):116-127. PubMed ID: 33033370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
    Klein MD; Lee CR; Stouffer GA
    Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease.
    Rashedi S; Sadeghipour P; Lou J
    Thromb Res; 2024 Apr; 236():240-241. PubMed ID: 38503672
    [No Abstract]   [Full Text] [Related]  

  • 17. Clopidogrel pharmacogenetics: from evidence to implementation.
    Cavallari LH; Duarte JD
    Future Cardiol; 2016 Sep; 12(5):511-4. PubMed ID: 27539287
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician response to implementation of genotype-tailored antiplatelet therapy.
    Peterson JF; Field JR; Unertl KM; Schildcrout JS; Johnson DC; Shi Y; Danciu I; Cleator JH; Pulley JM; McPherson JA; Denny JC; Laposata M; Roden DM; Johnson KB
    Clin Pharmacol Ther; 2016 Jul; 100(1):67-74. PubMed ID: 26693963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.
    Yang Y; Lewis JP; Hulot JS; Scott SA
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1599-617. PubMed ID: 26173871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
    Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.